Research ArticleMetabolism, Transport, and Pharmacogenomics
Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir
Matthew P. Kosloski, Daniel A.J. Bow, Ryota Kikuchi, Haoyu Wang, Elaine J. Kim, Kennan Marsh, Federico Mensa, Jens Kort and Wei Liu
Journal of Pharmacology and Experimental Therapeutics August 2019, 370 (2) 278-287; DOI: https://doi.org/10.1124/jpet.119.256966
Matthew P. Kosloski
AbbVie Inc., North Chicago, Illinois
Daniel A.J. Bow
AbbVie Inc., North Chicago, Illinois
Ryota Kikuchi
AbbVie Inc., North Chicago, Illinois
Haoyu Wang
AbbVie Inc., North Chicago, Illinois
Elaine J. Kim
AbbVie Inc., North Chicago, Illinois
Kennan Marsh
AbbVie Inc., North Chicago, Illinois
Federico Mensa
AbbVie Inc., North Chicago, Illinois
Jens Kort
AbbVie Inc., North Chicago, Illinois
Wei Liu
AbbVie Inc., North Chicago, Illinois
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMetabolism, Transport, and Pharmacogenomics
Transporter DDI for Glecaprevir and Pibrentasvir
Matthew P. Kosloski, Daniel A.J. Bow, Ryota Kikuchi, Haoyu Wang, Elaine J. Kim, Kennan Marsh, Federico Mensa, Jens Kort and Wei Liu
Journal of Pharmacology and Experimental Therapeutics August 1, 2019, 370 (2) 278-287; DOI: https://doi.org/10.1124/jpet.119.256966
Research ArticleMetabolism, Transport, and Pharmacogenomics
Transporter DDI for Glecaprevir and Pibrentasvir
Matthew P. Kosloski, Daniel A.J. Bow, Ryota Kikuchi, Haoyu Wang, Elaine J. Kim, Kennan Marsh, Federico Mensa, Jens Kort and Wei Liu
Journal of Pharmacology and Experimental Therapeutics August 1, 2019, 370 (2) 278-287; DOI: https://doi.org/10.1124/jpet.119.256966
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement